Cadence, a digital health startup, raised $100 million at a $1.23 billion valuation to automate chronic disease care using regulated artificial intelligence. The company focuses on managing conditions like hypertension and diabetes through remote monitoring and AI-guided treatment adjustments.
The funding underscores growing investor appetite for AI-powered healthcare solutions that reduce costs and improve outcomes. Cadence's platform is classified as a medical device, requiring FDA clearance, which sets it apart from less regulated wellness apps.
Revenue figures and patient count were not disclosed. However, the company stated its current modules cover three common chronic conditions, with plans to expand to more in coming years. The round was led by existing investors.
Regulatory hurdles remain a key challenge. AI-based medical devices face stringent FDA oversight, and any algorithm errors could lead to patient harm or liability. The market for chronic disease management is also crowded with competitors like Livongo and Omada Health.
"Automation in chronic care has massive potential, but trust and safety are paramount," said a healthcare analyst unaffiliated with Cadence. The company will need to prove its AI's efficacy at scale to maintain momentum.